MicroRNA-106b promotes the proliferation, migration and invasion of retinoblastoma cells by inhibiting the expression of ZBTB4 protein

WENJUAN BU1*, YANHUI WANG2* and XIANGRONG MIN1

1Department of Ophthalmology, Jining No. 1 People's Hospital, Jining, Shandong 272011; 2Department of Fundus Surgery, Hebei Province Eye Hospital, Xingtai, Hebei 054000, P.R. China

Received January 20, 2017; Accepted December 6, 2017

DOI: 10.3892/etm.2018.6811

Abstract. The present study investigated the function of microRNA (miR)-106b in the proliferation, migration and invasion of retinoblastoma (RB) cells, and aimed to elucidate the underlying mechanism. A total of 56 patients with RB were enrolled in the present study. The expression of miR-106b in RB tissues was measured by reverse transcription quantitative polymerase chain reaction. After transfection with miR-106b mimics or miR-106b inhibitor, a Cell-Counting kit-8 assay was used to determine the proliferation of WERI-Rb-1 cells and a Transwell assay was employed to measure the migration and invasion of the cells. Western blot analysis was performed to determine the expression of zinc finger and BTB domain containing 4 (ZBTB4) protein. After transfection with miR-106b mimics or miR-106b inhibitor, a Cell-Counting kit-8 assay was used to determine the proliferation of WERI-Rb-1 cells and a Transwell assay was employed to measure the migration and invasion of the cells. Western blot analysis was performed to determine the expression of zinc finger and BTB domain containing 4 (ZBTB4) protein. By silencing or overexpression of ZBTB4 protein, the biological functions of ZBTB4 in WERI-Rb-1 cells were studied. A dual luciferase reporter assay was performed to test whether ZBTB4 was a target gene of miR-106b. The expression of miR-106b in RB tissues was elevated and closely associated with the severity of the disease. Overexpression of miR-106b increased but inhibition of miR-106b expression decreased the proliferation, migration and invasion abilities of WERI-Rb-1 cells. In addition, overexpression of miR-106b decreased but inhibition of miR-106b expression increased ZBTB4 protein expression in WERI-Rb-1 cells. Similarly, overexpression of ZBTB4 reduced but inhibition of ZBTB4 expression promoted the proliferation, migration and invasion of WERI-Rb-1 cells. Finally, miR-106b regulated the expression of ZBTB4 by binding to the 3'-untranslated region of the ZBTB4 gene.

The present study demonstrated that increased expression of miR-106b in RB tissues is positively associated with the metastasis and differentiation of RB cells. As an oncogene, miR-106b promotes the proliferation, migration and invasion of WERI-Rb-1 cells by inhibiting the expression of ZBTB4 protein.

Introduction

Retinoblastoma (RB) is the most common type of primary intraocular malignant tumor in pediatric patients that has an occult onset and a high degree of malignancy (1). Without treatment, affected pediatric patients generally die within 1-2 years (2). Invasion and metastasis are the leading causes of death in pediatric patients with RB, making the disease a complex process that involves multiple genes, factors and procedures (3,4). In recent years, enucleation has been excluded from the treatment options for RB, and different treatments are adopted according to the different stages of the tumor, aiming to retain the eyes and their functions (5). Chemoreduction, mainly systemic chemotherapy, has become the first-line approach for the clinical treatment of RB (6,7). It greatly improved the survival rate of the patients without affecting the structure and function of eyeballs. However, failure of RB treatment remains common in clinical practice due to two reasons. First, tumor cells may develop resistance to drugs (8); furthermore, continued use of chemotherapeutic drugs may induce bone marrow suppression and secondary leukemia, increasing the mortality risk of the patients (9). Therefore, it is of great clinical significance to develop a safer and more effective adjuvant therapy for the treatment of patients with RB.

MicroRNAs (miRNAs or miRs) are non-coding small RNA molecules of 18-22 nucleotides in length that regulate mRNA translation by binding with the 3'-untranslated region (UTR) of their target mRNAs (10,11). miRNA molecules widely exist in eukaryotes and participate in multiple pathological processes. It has been reported that a variety of miRNA molecules act as oncogenes or tumor-suppressor genes in RB (12). For instance, miR-21 promotes the occurrence and development of RB by activating phosphatase and tensin homologue (PTEN)/phosphoinositide-3 kinase (PI3K)/AKT...
signaling pathway, and miR-21 inhibitor blocks the function of miR-21 (13). Bai et al (14) reported that miR-125b promotes the proliferation and inhibits the apoptosis of RB cells by targeting DNA damage-regulated autophagy modulator 2 gene expression. Zhang et al (15) reported that miR-125a-5p enhances the proliferation of RB cells by activating taffazin-epithelial growth factor receptor signaling pathway.

miR-106b is a member of the miR-106-25 family, which also includes miR-25 and miR-93 (16,17). The expression of miR-106b in gastric cancer tissues is significantly higher than that in adjacent normal tissue, and abnormal expression of miR-106b is observed in the peripheral blood of gastric cancer patients, suggesting that miR-106b has an important role in the occurrence and development of gastric cancer (18). Dai et al (19) discovered that miR-106b promotes the invasion and migration of esophageal squamous cancer cells in a Kazakh population by downregulating the expression of Smad7. Li et al (20) reported that miR-106b increases the proliferation, invasion and migration of breast cancer cells by regulating the expression of α-(1,3)-fucosyltransferase. These studies suggest that miR-106b has varied functions and mechanisms of action in different types of tumor. However, the expression and mechanism of action of miR-106b in RB has remained to be elucidated. The present study investigated the function of miR-106b in the proliferation, invasion and migration of RB cells, and aimed to elucidate the underlying mechanisms.

Patients and methods

Patients. A total of 56 patients (34 males and 22 females; age range, 2 months-11 years; mean age, 35.5±8.5 months) who received treatment for RB at Jining First People’s Hospital between December 2013 and December 2015 were enrolled in the present study. No patients received any chemotherapy or other treatments prior to sampling. Additionally, patients with chronic, genetic or autoimmune diseases were excluded from the present study. Among the patients, 36 had RB in one eye and 20 had RB in both eyes. According to the degrees of optic nerve invasion, the patients were divided into four groups according to tumor necrosis metastasis staging system: N0, RB did not invade optic nerves (n=9); N1, RB invaded optic papilla, but did not exceed sieve plate (n=6); N2, RB passed through sieve plate, but did not invade the end of optic nerves (n=25); and N3, RB cells were identified at the end of optic nerves (n=16) (21). Depending on whether RB cells were arranged into a Flexner-Winterstein rose ring, RB tissues were stratified into a high-differentiation group (n=39 cases) and a poor-differentiation group (n=17). Furthermore, normal retinal tissues were obtained from the adjacent tissues of RB tissues from 20 randomly selected patients. All procedures were approved by the Ethics Committee of Jining No. 1 People’s Hospital. Written informed consent was obtained from parents or guardians of all pediatric patients.

Cell line, culture and transfection. The RB cell line WERI-Rb-1 (Cell Bank of the Chinese Academy of Sciences, Shanghai, China) was cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (BD Biosciences, Franklin Lakes, NJ, USA), 100 IU/ml penicillin and 100 IU/ml streptomycin at 37°C in an atmosphere with 5% CO2 and 70% humidity. The cells were passaged once every four days, and those in the logarithmic growth phase were collected for experiments. On the day before transfection, the cells (3x10^5) were seeded onto 24-well plates containing RPMI-1640 without fetal bovine serum or antibiotics. The cells were divided into negative control (NC) and miR-106b mimics groups. When reaching 70% confluency, 1.5 µl miR-negative control (NC), miR-106b mimics or miR-106b inhibitor (20 pmol/µl; RiboBio, Guangzhou, China) and 1 µl liposome (Lipofectamine 2000; Thermo Fisher Scientific, Inc. Waltham, MA, USA) were mixed with 50 µl OptiMem medium (Thermo Fisher Scientific, Inc.), respectively, in individual Eppendorf tubes. After standing still for 5 min, the mixtures in the two Eppendorf tubes were mixed and kept at room temperature for 20 min, followed by addition into each culture well. After 6 h of incubation, the medium was replaced with fresh RPMI-1640 medium supplemented with 10% fetal bovine serum, and the cells were cultured under normal conditions prior to use. For RNA interference or overexpression of the zinc finger and BTB domain containing 4 (ZBTB4) gene, WERI-Rb-1 cells were transfected with lentiviral vectors LV-puro-shR-ZBTB4 and LV-puro-ZBTB4, respectively (HanBio, Shanghai, China) with a multiplicity of infection of 20. An empty vector was used as a negative control. After incubation for 72 h, the cells were harvested for further use.

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR). RB and control tissues (100 mg) were ground into powder in liquid nitrogen and mixed with 1 ml TRIzol (Thermo Fisher Scientific, Inc.) for lysis. Total RNA was then extracted using the phenol chloroform method. The purity of the RNA was determined via the absorbance at 260 vs. 280 nm using ultraviolet spectrophotometry (Nanodrop ND2000; Thermo Fisher Scientific, Inc.). The complementary (c)DNA was obtained by reverse transcription from 1 µg RNA and stored at -20°C. Reverse transcription of mRNA was performed using the PrimeScript™ II First Strand cDNA Synthesis kit (Takara, Dalian, China), and reverse transcription of miRNA was performed using the One Step PrimeScript miRNA cDNA Synthesis kit (Takara).

The expression of miR-106b was determined using the SYBR Primerscript RT-PCR Kit (Takara, Dalian, China), using U6 as an internal reference. The reaction system (20 µl) contained 10 µl real-time quantitative PCR mix, 0.5 µl upstream primer (miR-106b: 5'-TAAAGTGCTGACAGTGCAGAT-3'), 0.5 µl downstream universal primer (provided by the kit), 2 µl cDNA and 7 µl double-distilled (dd)H2O. The reaction protocol was as follows: Initial denaturation at 95°C for 10 min, followed by 40 cycles of 95°C for 1 min and 60°C for 30 sec (iQ5, Bio-Rad Laboratories, Inc., Hercules, CA, USA). The 2-ΔΔCq method (22) was used to calculate the relative expression of miR-106b against the internal reference. Each sample was tested in triplicate for PCR amplification.

The SYBR Green RT-qPCR kit (Kapa Biosystems, Wilmington, MA, USA) was used to detect miRNA expression of ZBTB4, using GAPDH as an internal reference. The reaction system (20 µl) was composed of 10 µl SYBR EX Taq-Mix, 0.5 µl upstream primer (ZBTB4: 5'-TCCCTTTTGGCAGTGA GGCTT-3'; GAPDH, 5'-CGGAGTCAACGGATTTGGTGC-3')
TAT-3'-), 0.5 µl downstream primer (ZBTB4, 5'-AGAAGG
GACCTGGAAGCAGCC-3'; GAPDH, 5'-AGCCTTCTCCAT
GGTGTTGAAGAC-3'), 5 µl cDNA and 4 µl ddH₂O. The PCR
conditions were as follows: Initial denaturation at 95°C for
10 min; 40 cycles of denaturation at 95°C for 1 min, annealing
at 60°C for 40 sec and elongation at 72°C for 30 sec; and final
elongation at 72°C for 1 min (iQ5; Bio-Rad Laboratories, Inc.).
The 2^ΔΔCt method was used to calculate the relative expression
of ZBTB4 mRNA against GAPDH. Each sample was tested in
triplicate.

**Cell Counting kit 8 (CCK-8) assay.** Cells were seeded at
2,000/well in 96-well plates for transfection. At 48 h after
transfection, the cells were subjected to the CCK-8 assay for
the detection of proliferation. At 0, 24 and 48 h, the medium
was discarded and the cells were washed with PBS twice,
followed by addition of 20 µl CCK-8 reaction reagent (5 g/l)
diluted in medium. On the last day, 150 µl CCK-8 reaction
solution was added and the cells were incubated at 37°C for
2 h. The absorbance of each well was measured at 490 nm for
plotting the cell proliferation curves. Each group was tested in
3 replicate wells and the values were averaged. Each experi-
ment was performed in triplicate.

**Transwell assay.** For the invasion assay, Matrigel was
thawed at 4°C overnight and diluted at 1:2 with serum-free
RPMI-1640 medium. The mixture (50 µl) was evenly smeared
into the upper chambers of a Transwell insert (pore size,
0.8 µm; EMD Millipore, Billerica, MA, USA) and incubated
at 37°C for 1 h to solidify. For both the invasion and migration
assay, 1x10^5 cells from each group were then seeded into the
upper chamber in 200 µl serum-free RPMI-1640 medium.
In addition, 500 µl RPMI-1640 medium supplemented with
10% fetal bovine serum was added into the lower chamber.
After 24 h, the cells in the upper chambers were wiped off.
After fixing of the membranes with 4% formaldehyde for
10 min, the membrane was stained at room temperature for
2 min using the Giemsa method for microscopic observation
of 5 random fields (magnification, x200). The number of cells
that had transgressed through the membrane was calculated
for the evaluation of cell invasion and migration ability. All
procedures were performed on ice with pipetting tips being
cooled at 4°C.

Western blot analysis. Tissues or cells were ground into
powder in liquid nitrogen and 100 mg of the powder was
mixed with 100 µl pre-cooled radioimmunoprecipitation
assay lysis buffer containing 1% phenylmethylsulfonyl
fluoride for lysis overnight at 4°C. The mixture was then
centrifuged at 12,000 x g and 4°C for 10 min. The super-
natant was used to determine the protein concentration by
the bicinchoninic acid protein concentration determination
kit (cat. no. RTP7102; Real-Times Biotechnology Co., Ltd.,
Beijing, China). Protein samples (50 µg) were then mixed with
5X SDS loading buffer prior to denaturation in a boiling
water bath for 10 min. Subsequently, the samples (10 µl) were
subjected to 10% SDS-PAGE at 100 V. The resolved proteins
were transferred to polyvinylidene difluoride membranes
(Bio-Rad Laboratories, Inc.) on ice (250 mA, 1 h) and
blocked with 50 g/l skimmed milk at room temperature
for 1 h. The membranes were then incubated with rabbit
anti-human ZBTB4 (1:1,000 dilution; cat. no. ab106554;
Abcam, Cambridge, UK) and GAPDH (1:4,000 dilution; cat.
no. ab9485; Abcam) polyclonal primary antibodies at 4°C
overnight. After extensive washing with PBS containing
Tween-20 (PBST) for 5 times for 5 min each, the membranes
were incubated with polyclonal goat anti-rabbit horseradish
peroxidase-conjugated secondary antibody (1:4,000 dilution;
cat. no. ab6721; Abcam) for 1 h at room temperature prior
to washing with PBST as above. The membrane was then
developed with an enhanced chemiluminescence detection
kit (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) for
imaging. Image lab v3.0 software (Bio-Rad Laboratories,
Inc.) was used to acquire and analyze imaging signals.
The relative expression of ZBTB4 protein was calculated
against GAPDH.

**Dual luciferase reporter assay.** Bioinformatics predic-
tion is a powerful tool for the study of the functions of miRNAs. To
understand the regulatory mechanisms of miR-106b in RB,
miRanda (http://www.microrna.org/microrna/home.do),
TargetScan (http://www.targetscan.org), PiTa (http://genie.
weizmann.ac.il/pubs/mir07/mir07_data.html), RNAhybrid
(http://bibiserv.techfak.uni-bielefeld.de/rnahybrid/) and
PICTAR (http://pictar.mdc-berlin.de/) were used to predict
miRNAs that could be targeted by miR-106b, and identified
that miR-106b was able to potentially regulate ZBTB4.
According to the results of the bioinformatics analysis,
wild-type (WT) and mutant seed regions of miR-106b in the
3'-UTR of the ZBTB4 gene were chemically synthesized,
Spe-1 and HindIII restriction sites were added, and
the sequences were cloned into pMIR-REPORT luciferase
reporter plasmids (Ambion; Thermo Fisher Scientific,
Inc.). Plasmids (0.5 µg) with WT or mutant 3'-UTR DNA
sequences were co-transfected with miR-106b mimics
(100 nM; Sangon Biotech) into 293T cells. After cultivation
for 24 h, the cells were lysed using a dual luciferase reporter
assay kit (Promega Corp., Madison, WI, USA) according to
the manufacturer's protocols, and the fluorescence intensity
was measured using a GloMax 20/20 luminometer (Promega
Corp.). Using Renilla fluorescence activity as an internal
reference, the fluorescence values of each group of cells
were measured.

**Statistical analysis.** Statistical analysis was performed
using SPSS 17.0 software (IBM Corp., Armonk, NY, USA).
Measurement data were expressed as the mean ± standard
deviation. Differences between two groups were compared
using Student's t-test. Multigroup comparisons were made
using one-way analysis of variance. In the case of homoge-
neity of variance, the Least Significant Difference and the
Student-Newman-Keuls methods were used; in the case of
heterogeneity of variance, Tamhane's T2 or Dunnett's T3
method was used. P<0.05 was considered to indicate a statisti-
cally significant difference.

**Results**

Expression of miR-106b in RB tissues is elevated and
closely associated with the disease severity. To measure
the expression of miR-106b in RB tissues, RT-qPCR was performed. The results indicated that miR-106b levels in RB tissues were significantly higher than those in normal tissues (P<0.05; Fig. 1A). In addition, the levels of miR-106b in the N2 and N3 groups were significantly higher than those in the N0 and N1 groups (P<0.05; Fig. 1B). Furthermore, miR-106b expression in the poor-differentiation group was significantly higher than that in the high-differentiation group (P<0.05; Fig. 1C). These results suggest that the expression of miR-106b in RB tissues is elevated and closely associated with the severity of the disease.

Overexpression of miR-106b increases but inhibition of miR-106b expression decreases the proliferation ability of WERI-Rb-1 cells. To determine the proliferation of WERI-Rb-1 cells, a CCK-8 assay was used. The results indicated that the absorbance of cells transfected with miR-106b mimics was significantly higher than that in the miR-NC group at 24 and 48 h (P<0.05), while the absorbance of cells transfected with miR-106b inhibitor was significantly lower than that in the miR-NC group at 24 and 48 h (P<0.05; Fig. 2). This result indicated that overexpression of miR-106b increases but inhibition of miR-106b expression decreases the proliferation ability of WERI-Rb-1 cells.

Overexpression of miR-106b increases but inhibition of miR-106b expression decreases the migration and invasion abilities of WERI-Rb-1 cells. To study the effect of
miR-106b on the migration and invasion of WERI-Rb-1 cells, a Transwell assay was performed. The results indicated that the numbers of cells in the miR-106b mimics group that transgressed through the Transwell membrane in the migration and invasion assays were significantly higher than those in the miR-NC group (P<0.05 for both; Fig. 3A and B). In addition, the numbers of cells in the miR-106b inhibitor group that transgressed through the Transwell membrane in the migration and invasion assays were significantly reduced compared with those in the miR-NC group (P<0.05 for both; Fig. 3C and D). These results suggest that overexpression of miR-106b increases but inhibition of miR-106b expression decreases the migration and invasion abilities of WERI-Rb-1 cells.

Overexpression of miR-106b decreases but inhibition of miR-106b expression increases ZBTB4 protein expression in WERI-Rb-1 cells. To examine the expression of ZBTB4 protein, western blot analysis was employed. The results indicated that ZBTB4 expression in cells transfected with miR-106b mimics was significantly reduced compared with that in the respective miR-NC group (P<0.05), but that in cells transfected with miR-106b inhibitor was significantly increased (P<0.05; Fig. 4A). In addition, WERI-Rb-1 cells with silencing of ZBTB4 by transfection with lentiviral vector had a significantly reduced expression of ZBTB4 protein compared with that in the NC group (P<0.05; Fig. 4B). The results indicate that overexpression of miR-106b decreases but inhibition of miR-106b expression increases ZBTB4 protein expression in WERI-Rb-1 cells.

Overexpression of ZBTB4 reduces but inhibition of ZBTB4 expression promotes the proliferation, migration and invasion of WERI-Rb-1 cells. To assess the effect of ZBTB4 protein expression on the biological function of WERI-Rb-1 cells, a CCK-8 assay and Transwell assay were performed on cells with silenced expression or overexpression of ZBTB4. The results indicated that the absorbance of cells transfected with siR-ZBTB4 was significantly higher than that of cells transfected with siR-NC at 24 and 48 h (P<0.05), while the absorbance of cells in the ZBTB4 group was significantly lower than that of cells transfected with NC at 24 and 48 h (Fig. 5). The Transwell assay indicated that the numbers of cells in the siR-ZBTB4 group that transgressed through the Transwell membrane in the migration and invasion assays were significantly higher than those in the NC group (P<0.05 for both; Fig. 6A and B). In addition, the numbers of cells in the ZBTB4 group that transgressed through the Transwell membrane in the migration and invasion assays were significantly reduced compared with those in the NC group (P<0.05 for both; Fig. 6C and D). These results suggest that overexpression of ZBTB4 reduces but inhibition of ZBTB4 expression promotes the proliferation, migration and invasion of WERI-Rb-1 cells.
miR-106b inhibits the expression of ZBTB4 by binding with the 3'-UTR of ZBTB4 mRNA. To understand whether miR-106b directly targets ZBTB4, a dual luciferase reporter assay was performed. The results demonstrated that transfection with miR-106b mimics and pMIR-REPORT-wild-type ZBTB4 led to significantly reduced fluorescence intensity compared with that in the negative control miR-transfected sample (P<0.05), while transfection with miR-106b mimics and pMIR-REPORT-mutant ZBTB4 resulted in similar fluorescence intensity compared with that in the negative control miR-transfected sample (P>0.05; Fig. 7). This result indicates that miR-106b regulates the expression of ZBTB4 by binding with the 3'-UTR of ZBTB4 mRNA.

Discussion

Certain miRNAs have important roles in the occurrence and development of tumors. Members of the miR-106b-25 family display abnormal expression in multiple tumor tissues and peripheral blood, participating in the regulation of proliferation, apoptosis, invasion and metastasis of tumors (23). For instance, the expression of the miR-106b-25 cluster is elevated in recurrent acute myeloid leukemia in pediatric patients caused by mixed lineage leukemia gene rearrangement, suggesting that miR-106b-25 is closely associated with the recurrence of acute myeloid leukemia (24). Zheng et al (25) discovered that miR-106b induces radiotherapy resistance of colon cancer cells by regulating the PTEN/Pi3K/AKT signaling pathway and p21 expression. It has been reported that miR-106b-25 cluster expression is elevated in gastric cancer tissues and peripheral blood of patients, and promotes the proliferation, invasion and metastasis of gastric cancer cells (23). In the present study, it was discovered that miR-106b expression is significantly increased in RB tissues, and patients at N2 and N3 stages had higher miR-106b levels than patients at N0 and N1 stages, suggesting that miR-106b expression is associated with the invasion and metastasis of RB. Regarding the degree of differentiation, miR-106b expression in the poor-differentiation group was significantly higher than that in the high-differentiation group, indicating that miR-106b expression is associated with RB cell differentiation. At the
cellular level, silencing of miR-106b expression inhibited the proliferation, migration and invasion of WERI-Rb-1 cells, while overexpression of miR-106b had the opposite effect, suggesting that miR-106b acts as an oncogene in RB.

The ZBTB protein family is a class of proteins that have a BTB domain at the N-terminus and multiple zinc finger domains at the C-terminus (26,27). Most members of the ZBTB family have a transcription factor function. ZBTB4, a member of the ZBTB family comprising 1,013 amino acids, has 1 BTB domain at N-terminus and 6 C2H2-type zinc finger structures at the C-terminus. ZBTB4 is a phosphorylation substrate for homeodomain-interacting protein kinase 2, and its phosphorylation induces the degradation of ZBTB4 protein and DNA injury (28). It was also reported that ZBTB4 directly binds to the promoter of p21 with the assistance of ZBTB17, inhibits p21 transcription, prevents cell cycle arrest via p21 after DNA injury and induces apoptosis (29). The bioinformatics study performed in the present study suggested that ZBTB4 mRNA is one of the potential targets of miR-106b. Western blot analysis and the dual luciferase reporter assay demonstrated that miR-106b directly binds to the 3'-UTR of ZBTB4 and reduces the expression of ZBTB4 protein. By contrast, miR-106b inhibitor increased the expression of ZBTB4 protein in WERI-Rb-1 cells, suggesting that ZBTB4 is a target gene of miR-106b. Further loss- and gain-of-function experiments indicated that overexpression of ZBTB4 inhibits the proliferation, migration and invasion of WERI-Rb-1 cells,
while silencing of ZBTB4 expression reduces the proliferation, migration and invasion of WERI-Rb-1 cells, indicating that ZBTB4 has a tumour suppressor function in WERI-Rb-1 cells. At present, there are few reports on the effect of miR-106b in RB. Similar with breast cancer and cerebral tumors (30,31), miR-106b promotes the occurrence and development of RB. More importantly, the present study demonstrated that miR-106b regulates the biological activities of RB via ZBTB4 gene and elucidates its underlying mechanism. In conclusion, miR-106b promotes the proliferation, migration and invasion of RB cells by inhibiting ZBTB4 expression. It is a potential therapeutic target and biomarker for RB.

Acknowledgements

The authors would like to thank Jining No. 1 People's Hospital (Jining, China) for the provision of facilities. The authors would also like to thank Dr Shuyin Sun and Dr Jie Feng of the Department of Ophthalmology, Jining No. 1 People's Hospital for reading the manuscript and providing valuable suggestions.

Funding

No funding was received.

Availability of data and materials

The analyzed data sets generated during the present study are available from the corresponding author on reasonable request.

Authors' contributions

WB, YW and XM designed the study. WB and YW performed the experiments, and WB, YW and XM analyzed the data. All authors interpreted the results, and produced and approved the final manuscript.

Ethics approval and consent to participate

All procedures were approved by the Ethics Committee of Jining No. 1 People’s Hospital. Written informed consent was obtained from parents or guardians of all pediatric patients.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References


This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.